Neutralizing Antibody Escape during HIV-1 Mother-to-Child Transmission Involves Conformational Masking of Distal Epitopes in Envelope
暂无分享,去创建一个
Ruth Nduati | J. Overbaugh | R. Nduati | Julie Overbaugh | Leslie Goo | Caitlin Milligan | Cassandra A. Simonich | Leslie Goo | Caitlin Milligan | Cassandra Simonich
[1] Pascal Poignard,et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques , 2009, Nature Medicine.
[2] D. Katzenstein,et al. Maternal HIV‐1 Antibody and Vertical Transmission in Subtype C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.
[3] Bette T. Korber,et al. Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.
[4] E. Reinherz,et al. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface , 2009, Proceedings of the National Academy of Sciences.
[5] E. Halapi,et al. Comparison of variable region 3 sequences of human immunodeficiency virus type 1 from infected children with the RNA and DNA sequences of the virus populations of their mothers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[6] Lynn Morris,et al. Limited Neutralizing Antibody Specificities Drive Neutralization Escape in Early HIV-1 Subtype C Infection , 2009, PLoS pathogens.
[7] Tongqing Zhou,et al. Mechanism of Human Immunodeficiency Virus Type 1 Resistance to Monoclonal Antibody b12 That Effectively Targets the Site of CD4 Attachment , 2009, Journal of Virology.
[8] Rajesh P. Ringe,et al. Subtle alteration of residues including N-linked glycans in V2 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies. , 2012, Virology.
[9] L. Morris,et al. The C3-V4 Region Is a Major Target of Autologous Neutralizing Antibodies in Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[10] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[11] M. Sagar. HIV-1 transmission biology: selection and characteristics of infecting viruses. , 2010, The Journal of infectious diseases.
[12] D. Thea,et al. Neutralizing antibody and perinatal transmission of human immunodeficiency virus type 1. New York City Perinatal HIV Transmission Collaborative Study Group. , 1998, AIDS research and human retroviruses.
[13] D. Venzon,et al. Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype. , 1995, The Journal of pediatrics.
[14] H. Katinger,et al. Post-exposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques , 2003, AIDS.
[15] C. Chappey,et al. Genetic analysis of human immunodeficiency virus type 1 envelope V3 region isolates from mothers and infants after perinatal transmission , 1995, Journal of virology.
[16] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[17] A. Trkola,et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1 , 1996, Journal of virology.
[18] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[19] J. Sodroski,et al. Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change , 1994, Journal of virology.
[20] M. Reitz,et al. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site. , 1993, Virology.
[21] Mario Roederer,et al. Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.
[22] F. Bibollet-Ruche,et al. Role of V1V2 and Other Human Immunodeficiency Virus Type 1 Envelope Domains in Resistance to Autologous Neutralization during Clade C Infection , 2007, Journal of Virology.
[23] T. Matthews,et al. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[24] Xiping Wei,et al. Evidence for Potent Autologous Neutralizing Antibody Titers and Compact Envelopes in Early Infection with Subtype C Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.
[25] E. Rosenberg,et al. Epitopes Immediately below the Base of the V3 Loop of gp120 as Targets for the Initial Autologous Neutralizing Antibody Response in Two HIV-1 Subtype B-Infected Individuals , 2011, Journal of Virology.
[26] Xuesong Yu,et al. Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.
[27] Sriram Subramaniam,et al. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures , 2011, Proceedings of the National Academy of Sciences.
[28] Maxim N. Artyomov,et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation , 2010, Nature.
[29] Marleen Temmerman,et al. Diversity of the Human Immunodeficiency Virus Type 1 (HIV-1) env Sequence after Vertical Transmission in Mother-Child Pairs Infected with HIV-1 Subtype A , 2003, Journal of Virology.
[30] Karina Yusim,et al. Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.
[31] Charles Wood,et al. Phylogenetic and phenotypic analysis of HIV type 1 env gp120 in cases of subtype C mother-to-child transmission. , 2002, AIDS research and human retroviruses.
[32] Robert A. Rasmussen,et al. Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.
[33] Joseph Sodroski,et al. Stoichiometry of Antibody Neutralization of Human Immunodeficiency Virus Type 1 , 2005, Journal of Virology.
[34] M. Reitz,et al. Generation of a neutralization-resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene , 1988, Cell.
[35] J. Levy,et al. Features of HIV-1 that could influence maternal-child transmission. , 1994, JAMA.
[36] Hui Li,et al. Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection , 2007, Journal of Virology.
[37] A. Perelson,et al. A Signature in HIV-1 Envelope Leader Peptide Associated with Transition from Acute to Chronic Infection Impacts Envelope Processing and Infectivity , 2011, PloS one.
[38] C. Blish,et al. Enhancing Exposure of HIV-1 Neutralization Epitopes through Mutations in gp41 , 2008, PLoS medicine.
[39] F. Onyango,et al. Effect of breastfeeding and formula feeding on transmission of HIV-1: a randomized clinical trial. , 2000, JAMA.
[40] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[41] Robyn L Stanfield,et al. Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[42] M. Reitz,et al. The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope , 1990, Journal of virology.
[43] M. Altfeld,et al. Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.
[44] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[45] J. Albert,et al. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.
[46] B. Korber,et al. Selective transmission of human immunodeficiency virus type-1 variants from mothers to infants. , 1992, Science.
[47] J. Overbaugh,et al. Cloning and characterization of functional subtype A HIV-1 envelope variants transmitted through breastfeeding. , 2007, Current HIV research.
[48] J. Overbaugh,et al. HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. , 2002, AIDS research and human retroviruses.
[49] O. Nishimura,et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[50] P. Clapham,et al. Genotypic and functional properties of early infant HIV-1 envelopes , 2011, Retrovirology.
[51] Young Do Kwon,et al. Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9 , 2011, Nature.
[52] Hong Zhang,et al. The Human Immunodeficiency Virus Type 1 Envelope Confers Higher Rates of Replicative Fitness to Perinatally Transmitted Viruses than to Nontransmitted Viruses , 2008, Journal of Virology.
[53] A. West,et al. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10 , 2009, Proceedings of the National Academy of Sciences.
[54] S. Lamers,et al. Independent variation and positive selection in env V1 and V2 domains within maternal-infant strains of human immunodeficiency virus type 1 in vivo , 1993, Journal of virology.
[55] D R Burton,et al. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.
[56] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[57] G. Sapiro,et al. Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.
[58] Yan Liu,et al. A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.
[59] Susan Zolla-Pazner,et al. A Global Neutralization Resistance Phenotype of Human Immunodeficiency Virus Type 1 Is Determined by Distinct Mechanisms Mediating Enhanced Infectivity and Conformational Change of the Envelope Complex , 2000, Journal of Virology.
[60] C. Kankasa,et al. Functional properties of the HIV-1 subtype C envelope glycoprotein associated with mother-to-child transmission. , 2010, Virology.
[61] L. Morris,et al. Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.
[62] D. Richman,et al. Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[63] S. Zolla-Pazner,et al. The V1/V2 Domain of gp120 Is a Global Regulator of the Sensitivity of Primary Human Immunodeficiency Virus Type 1 Isolates to Neutralization by Antibodies Commonly Induced upon Infection , 2004, Journal of Virology.
[64] H. Katinger,et al. Anti-Human Immunodeficiency Virus Type 1 (HIV-1) Antibodies 2F5 and 4E10 Require Surprisingly Few Crucial Residues in the Membrane-Proximal External Region of Glycoprotein gp41 To Neutralize HIV-1 , 2005, Journal of Virology.
[65] Dorothy M. Lang,et al. Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.
[66] J. Goudsmit,et al. Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies , 1993, Journal of virology.
[67] Peter D. Kwong,et al. The antigenic structure of the HIV gp120 envelope glycoprotein , 1998, Nature.
[68] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[69] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[70] S. Gnanakaran,et al. Escape from Autologous Neutralizing Antibodies in Acute/Early Subtype C HIV-1 Infection Requires Multiple Pathways , 2009, PLoS pathogens.
[71] Pham Phung,et al. Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.
[72] Pham Phung,et al. Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.
[73] F. Barin,et al. Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-infant pairs display a wide spectrum of biological properties. , 2012, Virology.
[74] A. Bartesaghi,et al. Molecular Architectures of Trimeric SIV and HIV-1 Envelope Glycoproteins on Intact Viruses: Strain-Dependent Variation in Quaternary Structure , 2010, PLoS pathogens.
[75] J. Albert,et al. Rapid development of isolate-specific neutralizing antibodies after primary HIV-1 infection and consequent emergence of virus variants which resist neutralization by autologous sera. , 1990, AIDS.
[76] Huldrych F. Günthard,et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies , 2011, The Journal of experimental medicine.
[77] Barbra A. Richardson,et al. Neutralization Escape Variants of Human Immunodeficiency Virus Type 1 Are Transmitted from Mother to Infant , 2006, Journal of Virology.
[78] Feng Gao,et al. Recurrent Signature Patterns in HIV-1 B Clade Envelope Glycoproteins Associated with either Early or Chronic Infections , 2011, PLoS pathogens.
[79] D. Montefiori,et al. The Genetic Bottleneck in Vertical Transmission of Subtype C HIV-1 Is Not Driven by Selection of Especially Neutralization-Resistant Virus from the Maternal Viral Population , 2011, Journal of Virology.
[80] Jerome H. Kim,et al. Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.
[81] C. Fundarò,et al. Antibody‐dependent cellular cytotoxicity and neutralizing activity in sera of HIV‐1‐infected mothers and their children , 1993, Clinical and experimental immunology.
[82] C. Blish,et al. The role of amino acid changes in the human immunodeficiency virus type 1 transmembrane domain in antibody binding and neutralization. , 2011, Virology.
[83] S. Spector,et al. Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. , 1999, The Journal of infectious diseases.
[84] Terri Wrin,et al. Novel Ring Structure in the gp41 Trimer of Human Immunodeficiency Virus Type 1 That Modulates Sensitivity and Resistance to Broadly Neutralizing Antibodies , 2009, Journal of Virology.
[85] D. Nickle,et al. Human Immunodeficiency Virus Type 1 Subtype B Ancestral Envelope Protein Is Functional and Elicits Neutralizing Antibodies in Rabbits Similar to Those Elicited by a Circulating Subtype B Envelope , 2005, Journal of Virology.